Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

High-Throughput Monitoring of Human Papillomavirus Type Distribution

In English

Författare

Summary, in English

Background: There is a need for a rapid and cost-effective evaluation of the effects of different human papillomavirus (HPV) vaccination strategies. Sexually active adolescents are a preferred target group for monitoring, as effects on HPV prevalence would be measurable shortly after implementation of vaccination programs. Methods: The Swedish Chlamydia trachomatis testing program offers free Chlamydia trachomatis testing and reaches a majority of all adolescents in the population. We anonymized the 44,146 samples submitted for Chlamydia trachomatis testing in Southern Sweden during March to November 2008 and conducted HPV genotyping using PCR followed by mass spectrometry. Results: The HPV positivity peaked at 54.4% [95% confidence interval (CI), 52.2-56.6] among 21-year-old women and at 15.0% (95% CI, 12.4-17.6) among 23-year-old men. The HPV positivity was 37.8% (95% CI, 37.3-38.3) for women and 11.2% (95% CI, 10.6-11.8) for men. The most prevalent types among women were HPV 16 (10.0%; 95% CI, 9.7-10.3) and HPV 51 (6.0%; 95% CI, 5.7-6.3) and, among men, HPV 16 (2.1%; 95% CI, 1.8-2.4) and HPV 6 and HPV 51 (1.7%; 95% CI, 1.5-1.9). Conclusion: The high HPV prevalences seen in the Chlamydia trachomatis screening population enables monitoring of the HPV type distribution among sexually active adolescents at high precision. Impact: Effectiveness of HPV vaccination programs in terms of reducing HPV infections has been difficult to measure because of logistic constraints. We describe a system for high-throughput monitoring of HPV type-specific prevalences using samples from the Chlamydia trachomatis screening program. Cancer Epidemiol Biomarkers Prev; 22(2); 242-50. (c) 2012 AACR.

Publiceringsår

2013

Språk

Engelska

Sidor

242-250

Publikation/Tidskrift/Serie

Cancer Epidemiology Biomarkers & Prevention

Volym

22

Issue

2

Dokumenttyp

Artikel i tidskrift

Förlag

American Association for Cancer Research

Ämne

  • Cancer and Oncology

Status

Published

Forskningsgrupp

  • Clinical Microbiology, Malmö

ISBN/ISSN/Övrigt

  • ISSN: 1538-7755